NCT02390362 - Randomized Trial Comparing Rituximab Against Mycophenolate Mofetil in Children Wtih Refractory Nephrotic Syndrome | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

December 7, 2016

Study Completion Date

January 18, 2017

Conditions

Frequent Relapsing Nephrotic SyndromeSteroid Dependent Nephrotic Syndrome

Interventions

DRUG

Rituximab

We hypothesize that the anti-CD20 monoclonal antibody Rituximab will be more effective in maintaining remission in children who have already had one relapse while receiving MMF

DRUG

MMF

Subjects randomized to MMF, will continue MMF as scheduled by the investigator

Trial Locations (1)

43205

Nationwide Children's Hospital, Columbus